ArticleAnnals of general psychiatry2025
The role of mindfulness training supported by virtual reality in the nonpharmacological treatment of schizophrenia-research design.
Article in Annals of general psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Schizophrenic Consciousness in the Light of the Phenomenological Epoché: A Foundational Map for Psychiatry.Brain sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper presents the outcome of a clinical trial planning process developed during multicenter, multidisciplinary seminars with prospective collaborators. The study protocol, designed according to the Oxford Quality Assessment System, outlines a randomized controlled trial (RCT) evaluating a novel Virtual Reality-based Mindfulness Skills Training (VR-MST) versus standard, non-VR MST in patients with schizophrenia (SZ). The trial aims to assess the effects of VR-MST on clinical outcomes, stress-related biomarkers, and gene expression.Eligibility criteria include: (1) SZ diagnosis based on ICD-10 and DSM-5 (2), psychotic symptom severity below 75 on the PANSS (moderately ill), and (3) age between 25 and 50 years. The protocol defines procedures for participant withdrawal and managing adverse events. The design tests both specific and general hypotheses, with pre- and post-intervention assessments in both groups, and additional pre-/post-session measurements in the VR group. Assessments span biological, symptomatic, and cognitive domains, using both objective and subjective measures.This study may inform clinical practice by introducing a novel, engaging, evidence-based, nonpharmacological intervention. VR-MST could support stress reduction, enhance cognitive functioning, and improve daily life in SZ patients. The design is grounded in prior pilot studies, literature reviews, and clinical expertise, aiming to provide a scalable and impactful therapeutic tool.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.